Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104009 | 0.74 | AHR (0.53) | AHR | |
| SCHEMBL3108896 | 0.71 | AHR (0.34) | AHRMAOAMAOBALOX5 | |
| SCHEMBL3106117 | 0.71 | AHR (0.33) | AHR | |
| SCHEMBL3105944 | 0.71 | AHR (0.33) | AHR | |
| SCHEMBL2956212 | 0.68 | NTSR1 (0.37) | AHR | |
| SCHEMBL3094025 | 0.68 | ALDH1A1 (0.38) | AHRMAPK1 | |
| SCHEMBL3100707 | 0.68 | P2RX7 (0.33) | AHR | |
| SCHEMBL8932796 | 0.68 | AHR (0.57) | AHRMAOAMAOBALOX5 | |
| SCHEMBL2362430 | 0.68 | AHR (0.57) | AHRMAOAMAOBALOX5 | |
| SCHEMBL125113 | 0.66 | MAOA (0.56) | AHRMAOAMAOBALOX5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | claimed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-8338608-B2 | Inhibitors of ion channels | ICAGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1945029-A2 | INHIBITORS OF ION CHANNELS | Icagen, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007056099-A2 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | AHR 1415/4885MAOA 2891/4885MAOB 2563/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | AHR 1415/4885MAOA 2891/4885MAOB 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.